Spots Global Cancer Trial Database for Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Official Title: A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Study ID: NCT00501605
Interventions
Study Description
Brief Summary: Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Freiburg, , Germany
Contact Details
Name: Nick Botwood, BSc, MBBS, MRCP, MFPM
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: J. Drevs, PD
Affiliation: Klinik fur.Internistische Onkologie
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
